Krishna Polu Net Worth

Krishna Polu biography

Dr. Krishna R. Polu M.D. is no longer serves as Executive Vice President - Research and Development, Chief Medical Officer of the Company effective 12/31/2020. Currently he is Chief Medical Officer of the Company. From February 2018 to August 2018, Dr. Polu served as Interim Chief Executive Officer of Scout Bio, Inc., a privately-held biotechnology company. Dr. Polu founded Expedition Therapeutics, Inc., a privately-held search company, in June 2017 and served as its Chief Executive Officer from June 2017 until August 2018. Dr. Polu also served as an Entrepreneur-in-Residence at Frazier Healthcare Partners, an investment firm, from February 2017 until August 2018. Prior to that, Dr. Polu served as the Chief Medical Officer of Raptor Pharmaceutical Corp., a publicly-held biopharmaceutical company, from January 2015 to December 2016. Dr. Polu also previously served as the Chief Medical Officer of CytomX Therapeutics, Inc., a privately-held biotechnology company, from March 2013 to June 2014. From July 2009 to March 2013, Dr. Polu served as Vice President of Clinical Development at Affymax, Inc., a publicly-held biopharmaceutical company. Prior to Affymax, Inc., Dr. Polu served as the Executive Director, Global Development of Amgen Inc., a publicly-held biotechnology company, from November 2007 to July 2009. Dr. Polu holds a B.A. in Human Biology from Stanford University and a M.D. from University of Texas Health Science Center, San Antonio. Dr. Polu also completed an internal medicine internship and residency at the University of Colorado as well as clinical and research fellowships in nephrology and transplant at Harvard Medical School in a joint program with Brigham and Women’s Hospital and Massachusetts General Hospital.

What is the salary of Krishna Polu?

As the Executive Vice President - Research and Development i Chief Medical Officer of Equillium Inc, the total compensation of Krishna Polu at Equillium Inc is $1,508,120. There are no executives at Equillium Inc getting paid more.

How old is Krishna Polu?

Krishna Polu is 46, he's been the Executive Vice President - Research and Development i Chief Medical Officer of Equillium Inc since 2020. There are 15 older and 2 younger executives at Equillium Inc. The oldest executive at Equillium Inc is Bala Manian, 74, who is the Independent Director.

What's Krishna Polu's mailing address?

Krishna's mailing address filed with the SEC is 2223 AVENIDA DE LA PLAYA, SUITE 108, , LA JOLLA, CA, 92037.

Insiders trading at Equillium Inc

Over the last 6 years, insiders at Equillium Inc have traded over $2,616,040 worth of Equillium Inc stock. The most active insiders traders include Daniel Bradbury, Mark Pruzanski oraz Stephen Connelly. On average, Equillium Inc executives and independent directors trade stock every 95 days with the average trade being worth of $20,757. The most recent stock trade was executed by Jason A Keyes on 16 July 2024, trading 10,000 units of EQ stock currently worth $8,700.

What does Equillium Inc do?

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.

Equillium Inc executives and stock owners

Equillium Inc executives and other stock owners filed with the SEC include:

• Krishna Polu,
  Executive Vice President - Research and Development, Chief Medical Officer
• Bruce Steel,
  President, Chief Executive Officer, Director
• Daniel Bradbury,
  Executive Chairman of the Board
• Dr. Krishna R. Polu,
  Consultant
• Dr. Stephen Connelly Ph.D.,
  Chief Scientific Officer & Director
• Bruce D. Steel C.F.A.,
  Co-Founder, Pres, CEO & Director
• Stephen Connelly,
  Chief Scientific Officer, Director
• Daniel Mark Bradbury,
  Exec. Chairman
• Mark Pruzanski,
  Independent Director
• Charles McDermott,
  Independent Director
• Bala Manian,
  Independent Director
• Martha Demski,
  Independent Director
• Matthew Ritter,
  Vice President - Corporate Development
• Maple Fung,
  Vice President - Clinical Development
• Christine Zedelmayer,
  Chief Operating Officer, Senior Vice President
• Jason Keyes,
  Chief Financial Officer
• Jason A. Keyes,
  Chief Financial Officer
• Dr. Dolca Thomas M.D.,
  Exec. VP of R&D and Chief Medical Officer
• Joel M. Rothman,
  Chief Devel. Officer
• Michael Moore,
  VP of Investor Relations & Corp. Communications
• Christine Zedelmayer M.B.A., P.M.P.,
  Sr. VP & COO
• Yu (Katherine) Xu,
  
• Sa Biocon,
  10% owner
• Dolca Thomas,
  Chief Medical Officer
• Joel Rothman,
  Chief Development Officer
• Barbara Troupin,